PROTEOLYTICALLY CLEAVABLE FUSION PROTEINS WITH HIGH MOLAR SPECIFIC ACTIVITY

Number of patents in Portfolio can not be more than 2000

United States of America Patent

SERIAL NO

13074153

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
CSL BEHRING GMBHEMIL VON BEHRING STRASSE 76 D-35041 MARBURG

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
METZNER, Hubert Marburg, DE 42 439
Schulte, Stefan Marburg, DE 76 678
Weimer, Thomas Gladenbach, DE 56 657

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation